EMA Outlines Medical Literature Monitoring for APIs


From DCAT Value Chain Insights (VCI)

By Regulatory News posted 05-18-2015 16:45

  

The European Medicines Agency (EMA) has published the list of active substances and a reference to the journals that will be covered by its new medical literature monitoring service. This service will start with a limited number of active substances on July 1, 2015 and will be fully rolled out in September 2015. A guide, a training video, and a document detailing the inclusion and exclusion criteria to be used when screening the literature are also available on a dedicated webpage.

Medical literature is an important source of information on suspected adverse reactions reported on medicines. The European Union's (EU) pharmacovigilance legislation has given the EMA responsibility for the monitoring of selected medical literature for a defined list of active substances used in medicines and for entering identified reports of suspected adverse reactions in the EudraVigilanceExternal link icon, the EU adverse drug reaction collection and management system.

The initiative seeks to improve the safety monitoring of medicines by enhancing the quality and consistency of data reported in EudraVigilance. It is provided as a service to industry which, for the active substances and literature covered by the EMA activities, will no longer be obliged to enter the information on suspected adverse reactions into EudraVigilance. Individual cases of suspected adverse reactions found in the literature will be made available to marketing-authorization holders so they can include them in their safety databases and meet their reporting obligations outside the European Economic Area.

A total of 400 active substance groups will be monitored by the EMA, in particular substances that are contained in a high number of medicinal products, and over 4,000 companies will benefit, according to the EMA. Following a public procurement procedure, EMA has selected a contractor to support the agency in the operation of this service. The EMA advises that companies should consult the documents published to find out whether their products are included in the service.

As of July 1, 2015, the service will cover the top 50 chemical active substance groups (ID 1 to ID 50) that are listed in the document. Companies with medicines containing one of these active substances will benefit from the EMA service from July 1, 2015 and will need to adapt their processes by that date. All the other substances, including the herbal active substances that are listed, will be included in the EMA service as of September 2015.

EMA said it will send updates on the implementation of its medical literature monitoring service to the qualified persons for pharmacovigilance as well as to pharmaceutical industry organizations. The dedicated webpage will also be regularly updated, according to the EMA.

Source: EMA

0 comments
29 views


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription 

Permalink